March 10, 2020 / 9:22 PM / 18 days ago

BRIEF-Phio Pharmaceuticals And Helmholtz Zentrum München Announce Collaboration And Option Agreement With Medigene

March 10 (Reuters) -

* PHIO PHARMACEUTICALS AND HELMHOLTZ ZENTRUM MÜNCHEN ANNOUNCE COLLABORATION AND OPTION AGREEMENT WITH MEDIGENE

* PHIO PHARMACEUTICALS CORP - MEDIGENE WILL CONTRIBUTE EXPERTISE REGARDING CLINICAL DEVELOPMENT AS WELL AS PROPRIETARY RESEARCH MATERIAL

* PHIO - MEDIGENE HAS OPTION TO EXCLUSIVE LICENSE FOR CLINICAL AND/OR COMMERCIAL EXPLOITATION OF POTENTIAL IMMUNE CELL ENHANCERS AGAINST FEE PAYMENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below